CTNM
NASDAQContineum Therapeutics Inc.
News25/Ratings5
Price$14.29+0.70 (+5.15%)
01:30 PM07:45 PM
News · 26 weeks62+700%
2026-01-182026-07-12
Mix3290d
- Insider14(44%)
- Other11(34%)
- SEC Filings7(22%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.SCHEDULE 13G/A - Contineum Therapeutics, Inc. (0001855175) (Subject)
- SECContineum Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
- INSIDERChief Scientific Officer Lorrain Daniel S. exercised 1,040 shares at a strike of $1.01 and sold $16,640 worth of shares (1,040 units at $16.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERCEO and President Stengone Carmine N. exercised 2,500 shares at a strike of $1.01 and sold $40,000 worth of shares (2,500 units at $16.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERChief Scientific Officer Lorrain Daniel S. exercised 33,009 shares at a strike of $1.01 and sold $594,578 worth of shares (37,179 units at $15.99) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 135,202 units (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERCMO & Head of Development Watkins Tim exercised 10,833 shares at a strike of $4.50 and sold $173,590 worth of shares (10,833 units at $16.02) as part of a pre-agreed trading plan (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERCEO and President Stengone Carmine N. exercised 10,000 shares at a strike of $1.07 and sold $160,080 worth of shares (10,000 units at $16.01) as part of a pre-agreed trading plan (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- PRContineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry- Manuscript describes the discovery of LPAR1 antagonist PIPE-791, now in a Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF)- Blocking LPAR1 inhibits key steps in the fibrosis pathway with potential targets in several therapeutic indicationsContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the publication of a manuscript describing the discovery and characterization of PIPE-791 in the Journal of Medicinal Chemistry. The article, "Discovery of PIPE-791, a Potent and
- INSIDERSEC Form 4 filed by Director Miralles Gines Diego4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERSEC Form 4 filed by Director Lyons-Williams Lori4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERSEC Form 4 filed by Director Ware Olivia C4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERSEC Form 4 filed by Director Schimmelpennink Evert B.4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERSEC Form 4 filed by Director Ignelzi Troy A.4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERSEC Form 4 filed by Director Brady Todd R.4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERSEC Form 4 filed by Director Boyce Sarah4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- SECContineum Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
- INSIDERChief Scientific Officer Lorrain Daniel S. sold $54,862 worth of shares (4,170 units at $13.16) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 139,372 units (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- PRContineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare ConferenceContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Goldman Sachs Global Healthcare Conference on Tuesday, June 9th at 1:20 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of Contineum's website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.SCHEDULE 13G/A - Contineum Therapeutics, Inc. (0001855175) (Subject)
- PRContineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on May 14, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 51,000 shares of Class A common stock to one new non-executive employee under the Company's 2026 Employment Inducement Equity Incentive Plan. The award was granted as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)
- SECSEC Form SCHEDULE 13G filed by Contineum Therapeutics Inc.SCHEDULE 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)
- PRContineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare ConferenceContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th at 3:35 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of Contineum's website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies f
- PRContineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International ConferenceContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced two scientific posters for its lead investigational drug candidate, PIPE-791, at the upcoming American Thoracic Society (ATS) 2026 International Conference. ATS 2026 will take place in Orlando, Fla. from May 15-20, 2026. The following abstracts are posted on ATS 2026's online itinerary planner for registered users. Title: PIPE-791 and BMS-986278: Two Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists With Distinct Lung Occupancy Profiles and
- SECSEC Form 10-Q filed by Contineum Therapeutics Inc.10-Q - Contineum Therapeutics, Inc. (0001855175) (Filer)
- SECContineum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
CTNM FAQ
6 questionsWhere does CTNM stock trade?
Contineum Therapeutics Inc. (CTNM) is listed on NASDAQ.What sector and industry is CTNM in?
Contineum Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Contineum Therapeutics Inc. go public?
Contineum Therapeutics Inc. (CTNM) completed its IPO in 2024.What are analysts saying about CTNM?
Contineum Therapeutics Inc. has had 5 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $1400.00 price target on 2026-01-08. Recent price targets range from $1400.00 to $3200.00.What companies are similar to CTNM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CTNM side-by-side with any of them on Quantisnow.How can I track CTNM on Quantisnow?
Quantisnow aggregates Contineum Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CTNM to receive live email and push alerts on every new disclosure.